The Technical Analyst
Select Language :
Theratechnologies Inc [THTX]

Exchange: NasdaqCM Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic

Theratechnologies Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Theratechnologies Inc is listed at the NASDAQ Exchange

0.68% $2.22

Last updated: 7 aug 2022 - 23:40

TimeZone: America/New_York


FUNDAMENTALS
MarketCap: 210.69 mill
EPS: -0.367
P/E: 0.000
Earnings Date: Oct 11, 2022
SharesOutstanding: 95.12 mill
Avg Daily Volume: 0.0448 mill
RATING 2022-08-05
B-
Neutral
RATINGDETAILS
Rating CashFlow: Strong Buy
Return On Equity: Strong Buy
Return On Asset: Sell
DE: Strong Sell
P/E: Sell
Price To Book: Strong Sell
QUARTER GROWTHS
1/212/213/214/211/222/22
Revenue
Gr.Profit
Ebit
Asset
Debt
DISCOUNTED CASH FLOW VALUE
$2.48
(11.96%) $0.265
Date: 2022-08-08
Expected Trading Range (DAY)

$ 2.11 - 2.32

( +/- 4.70%)
ATR Model: 14 days

Forecast: 16:00 - $2.22

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $2.22
Forecast 2: 16:00 - $2.22
Forecast 3: 16:00 - $2.22
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $2.22 (0.68% )
Volume 0.0386 mill
Avg. Vol. 0.0448 mill
% of Avg. Vol 86.23 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Theratechnologies Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Theratechnologies Inc

RSI

Intraday RSI14 chart for Theratechnologies Inc
The Live Chart for Theratechnologies Inc
Profile picture for
            Theratechnologies Inc

THTX

Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 32 full-time employees. The firm addresses medical needs to promote healthy living for human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). Ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The firm distributes EGRIFTA in the United States through RxC Acquisition.

Last 10 Buy Signals
Date Signal @
SYSUSDAug 7 - 23:380.187
GNOUSDAug 7 - 23:38163.72
DOGEUSDAug 7 - 23:38$0.0701
LSKUSDAug 7 - 23:381.217
PARTUSDAug 7 - 23:380.431
BATUSDAug 7 - 23:380.435
BTMUSDAug 7 - 23:380.0130
ZRXUSDAug 7 - 23:370.360
GBYTEUSDAug 7 - 23:3616.27
LRCUSDAug 7 - 23:360.481

Stock Peers

Company Price Change
THTX2.220.68%
ADAP2.340.86%
AUTL3.487.08%
CLPT15.571.04%
CMPI10.500.00%
EDAP7.624.38%
FDMT11.484.36%
IPHA2.76-0.36%
MOLN6.874.68%
OCUL4.962.06%
VSTM1.1905.31%

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.